Life Biosciences
Targeting the biology of aging
Targeting the biology of aging
Life Biosciences, founded in 2017 and headquartered in Boston, MA, is dedicated to developing novel therapies to extend healthy human lifespan by targeting the biological causes of aging. The company's slogan, "Targeting the biology of aging," aligns with its focus on pursuing therapies targeting three molecular pathways that regulate the biology of aging: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. This approach allows them to develop medicines with the potential to prevent, treat, and/or reverse multiple aging-related diseases, each with critical unmet needs. In its latest funding round, Life Biosciences secured an substantial $82.00M Series C investment on 05 January 2022. The investment was led by Alpha Wave Ventures, Abundance Partners, and George Godula. The company operates in the biotechnology and life sciences industries, positioning itself as a player at the forefront of longevity research and anti-aging therapies within the United States.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $82.00M | 3 | Alpha Wave Ventures, Abundance Partners +1 | 05 Jan 2022 |
| Venture Round | $74.77M | 1 |
|
29 May 2020 |
| Series B | $50.00M | 1 |
|
15 Jan 2019 |
| Series A | Unknown | 1 |
|
01 Oct 2018 |
No recent news or press coverage available for Life Biosciences.
We care about your data, and we'd love to use cookies make your experience better.
